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BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is associated with poor survival. To identify prognostic and
diagnostic markers and therapeutic targets, we studied ANO1, a recently identified calcium-activated chloride channel (CaCC).
METHODS: High-resolution genomic and transcriptomic microarray analysis and functional studies using HNSCC cell line and CaCC
inhibitors.
RESULTS: Amplification and overexpression of genes within the 11q13 amplicon are associated with the propensity for future distance
metastasis of HPV-negative HNSCC. ANO1 was selected for functional studies based on high correlations, cell surface expression
and CaCC activity. ANO1 overexpression in cells that express low endogenous levels stimulates cell movement, whereas
downregulation in cells with high endogenous levels has the opposite effect. ANO1 overexpression also stimulates attachment,
spreading, detachment and invasion, which could account for its effects on migration. CaCC inhibitors decrease movement, suggesting
that channel activity is required for the effects of ANO1. In contrast, ANO1 overexpression does not affect cell proliferation.
INTERPRETATION: ANO1 amplification and expression could be markers for distant metastasis in HNSCC. ANO1 overexpression
affects cell properties linked to metastasis. Inhibitors of CaCCs could be used to inhibit the tumourigenic properties of ANO1,
whereas activators developed to increase CaCC activity could have adverse effects.
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Head and neck squamous cell carcinoma (HNSCC) is common
worldwide and is associated with poor survival (Parkin et al, 1999,
2005; Dobrossy, 2005), mainly due to relapse, metastasis and
second cancer (Forastiere et al, 2001; Le Tourneau et al, 2005).
Owing to the increasing incidence of HNSCC, there is a growing
need for new prognostic and diagnostic markers and therapeutic
targets, as well as a better understanding of the biological functions
that contribute to clinical outcome. We have studied changes in
gene expression in HNSCC tumours compared with histologically
normal matched tissues, using differential display and microarray
analysis (Lemaire et al, 2003; Carles et al, 2006). This led to the
identification of a novel uncharacterised gene located on chromo-
somal region 11q13 that is overexpressed in HNSCC, which is now
called anoctamin 1 (ANO1, also called TMEM16A, ORAOV2, DOG1,
TAOS2 and FLJ10261). We showed that ANO1 is overexpressed at
the RNA and protein levels in HNSCC, predicted that ANO1 is a
membrane protein, and also suggested that it might be a good
candidate for targeted anticancer therapy (Carles et al, 2006). In
later studies, we compared tumours from patients with different
clinical outcomes (Rickman et al, 2008; Jung et al, 2010). The
propensity for subsequent distant metastasis in HNSCC was
analysed using primary tumours from patients initially treated by
surgery that developed (M) or did not develop (NM) metastases as
the first recurrent event. Transcriptome (Affymetrix HGU133_Plus2
(Paris, France), quantitative reverse transcriptase PCR) and array
comparative genomic hybridisation analysis identified transcripts
that were significantly associated with M/NM status, as well as
genomic areas including 11q13. However, the genomic analysis
was of low resolution, precluding the identification of changes at
the single gene level that could be linked to individual transcripts
(Rickman et al, 2008). We report here a reanalysis of the same
samples with genomic microarrays (Illumina 370K SNP, Paris,
France) that provided individual gene resolution, which rekindled
our interest in ANO1.
ANO1 consists of 26 exons and has been predicted to code for
a variety of proteins. It belongs to a protein family with eight
transmembrane helices and N- and C-termini that face the
cytoplasm (Katoh and Katoh, 2004; Galindo and Vacquier, 2005).
ANO1 has two conserved domains of unknown function, a domain
that could interfere in meiotic segregation, and multiple potential
glycosylation and phosphorylation sites (Katoh and Katoh, 2003).
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activated chloride channel (CaCC) (Caputo et al, 2008; Schroeder
et al, 2008; Yang et al, 2008). It is highly expressed in tissues with
high CaCC activity, and is required for normal development of
the trachea (Rock et al, 2008). Chloride channels are relatively
underexplored for drug discovery. They have roles in diverse
physiological processes, such as fluid secretion, olfactory percep-
tion, and neuronal and smooth muscle excitability. Mutations in
these channels cause human diseases, including cystic fibrosis, and
have applications in treating disorders, such as hypertension and
others. There are many opportunities for chloride channels in drug
discovery, including, for example, increasing ANO1 activity to
treat cystic fibrosis (Verkman and Galietta, 2009).
The ANO1 gene is located on 11q13 (Katoh and Katoh, 2003), a
chromosomal region that is frequently amplified in HNSCC and is
associated with poor outcome (for reviews, see Gollin, 2001; Katoh
and Katoh, 2003; West et al, 2004; Perez-Ordonez et al, 2006;
Espinosa et al, 2008; Haddad and Shin, 2008). Furthermore, ANO1
is one of a cassette of genes that have been suggested to drive
11q13 amplification by providing growth or metastatic advantage
to cancer cells (Huang et al, 2006). In this study, we report that
amplification and overexpression of ANO1 is highly correlated
with the future development of metastasis in HPV-negative
HNSCC. ANO1 is involved in cell motility, invasion and adhesion
of HNSCC cells, which could account for this clinical association.
Inhibitors of CaCC activity inhibit ANO1-induced migration,
suggesting that CaCC activity is important for cell movement.
These results raise the possibility that CaCC inhibitors could be
explored for tumour therapy.
MATERIALS AND METHODS
Patients and samples
Tumour samples were collected from the Biological Collection of
the Centre Paul Strauss. Patients were operated for primary
HNSCC between 1988 and 2003. Tumour samples were collected
at the time of surgery, with the patient’s informed consent.
A fragment was taken near the advancing edge of the primary
tumour (avoiding its necrotic centre), immediately frozen in
liquid nitrogen and stored at  801C. The rest of the tumour was
fixed in 6% buffered formaldehyde and embedded in paraffin for
histopathological analysis. The UICC TNM system (Staaf et al,
2008) was used for tumour-node-metastasis staging. Histological
examination of sections adjacent to each tumour fragment showed
that 60–80% were tumour cells.
A total of 83 samples were included in genome array analysis.
The criteria for inclusion were tumour localisation (oral cavity,
tongue, oropharynx and hypopharynx), no detectable human
papillomavirus genome, no clinically evident distant metastases by
conventional clinical and diagnostic radiological examinations
(computed tomography), surgical resection was the first treatment,
and at least 3mm of the surgical margins were histologically
tumour free. During the clinical follow-up, they either developed
distant metastases to the bone, lungs or liver as the first recurrence
(M, 39 cases) or did not (NM, 45 cases) (Supplementary Table 3).
Genomic transcriptomic and membrane topology analysis
Genomic profiles were obtained using Illumina 370K SNP
chips (n¼80; Arrayexpress E-TABM-994, http://www.ebi.ac.uk/
microarray-as/ae) and 4.7K CIT-CGH BAC arrays (n¼83;
Arrayexpress E-TABM-995 dataset). Transcriptomic profiles
(n¼83) of the same set of samples were previously described
(Rickman et al, 2008) (Arrayexpress E-TABM-302 dataset).
Pre-treatment steps are described in detail in the Supplementary
Materials and Methods.
Cells
HEp-2 clones were established by calcium phosphate transfection
with expression vectors for ANO1 or the corresponding
empty vector (pSG5-puromycin), selection for 18 days with
2mgml
–1 puromycin and isolation of individual clones. siRNAs
were transfected with lipofectamine (Invitrogen, Cercy-Pontoise,
France) for HEp-2 and lipofectamine 2000 (Invitrogen) for SCC-25.
Western blots
Cell lysates were made up to 1  Laemli buffer, heat denatured,
fractionated by 10% SDS polyacrylamide gel electrophoresis,
transferred to nitrocellulose membranes, and revealed with anti-
bodies (ANO1: PAb2069, 1/1000 (Carles et al, 2006); TBP:
MAb3G3, 1/2000, (IGBMC)), followed by HRP-conjugated second-
ary antibodies and the enhanced chemiluminescence kit (Pierce,
Illkirch, France).
Reverse transcriptase quantitative PCR
RNA was extracted with the GeneElute mammalian total RNA
miniprep kit (Sigma-Aldrich, Lyon, France), verified by agarose gel
electrophoresis for integrity, reverse transcribed with Superscript
II (RTase SC, Life Technologies) and oligodT primer (Sigma-
Aldrich), and amplified by quantitative PCR using a LightCycler
and LC Fast start DNA master SYBR green I kit (Roche
Diagnostics, Meylan, France). Quantitative PCRs for each experi-
ment were carried out at least twice. The primers were designed
by primer3 software (http://frodo.wi.mit.edu/primer3/). PCR
specificity was verified by melting curve analysis and agarose gel
electrophoresis. Standard curves were prepared using different
dilutions of cDNA for each pair of primers, and expression levels
were normalised with RPLP0.
Proliferation assays
Proliferation was measured with MTT (Chemicon International,
Inc., Molsheim, France). In all, 2000cells per well were seeded in 96-
well plates, and six wells were averaged for each time point. Growth
in soft agar (0.35% agarose, DIFCO Laboratories, Le Pont de Claix,
France) was analysed by plating 5000 cells per 35mm Petri dish on
1% agarose. Several drops of complete medium were added to the
plates once a week and, after 2–3 weeks, foci were stained with
0.005% crystal violet, photographed with a Nikon Coolpix 995
(Paris, France) and analysed using Image J (http://rsb.info.nih.gov/
ij/). Each clone was plated in quadruplet per experiment.
In vitro wound healing and time lapse microscopy
Cells were plated in duplicate in 24-well plates (Becton Dickinson,
Le Pont de Claix, France; ref. 353047), grown to confluence,
scraped with 200-ml disposable plastic pipette tips and washed with
phosphate-buffered saline. In some experiments, 5 or 10mM
aphidicolin (Sigma) was added before wounding. Images were
collected every 20min for 48h with an inverted microscope (Leica
DMRIB (St Jorioz, France), magnification  40, Hoffman con-
trast), a Cool Snap FX camera and Metamorph software (Universal
Imaging, Evry, France). The distances between the wound edges
were measured using Adobe Photoshop CS2. To study ANO1
inhibition, 60–80% confluent cells were transfected with siRNA
(25nM, HEp-2 clones; 50nM, SCC-25 cells), grown to confluence
(24–48h after transfection) and then wounded. To study the
effects of pharmacological inhibitors, the cells were seeded
(1.2 10
5) in 24-well plates, grown to confluence, wounded and
washed with phosphate-buffered saline. The wounded monolayers
were then incubated with the compounds or the solvent (DMSO
0.1%) and photographed after 0, 8, 24, 36 and 48h.
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Cell migration (on collagen I or BSA) and invasion (Matrigel plug)
assays were performed according to the manufacturer’s instructions
(collagen quantitative cell migration assay; Chemicon International,
Inc). The cells were plated in duplicate per experiment.
Cell adhesion, spreading and detachment assay
To measure adhesion, cells were plated (10
6cells per well in 6-well
plates), incubated for 10min at 371C, and adherent and non-
adherent (collected with two phosphate-buffered saline washes) cells
were counted. The cells were plated in duplicate per experiment. Cell
spreading and detachment assays were performed as described by
Rodrigues et al (2005) and Tchou-Wong et al (2006), respectively.
Statistical analysis
Statistical significance was assessed using Student’s t-test
(Microsoft Excel, Redmond, WA, USA). Univariate Cox models
were calculated using the coxph function from the survival
R package (http://www.r-project.org/). Genome transcriptome
correlations were calculated using the Pearson coefficient of
correlation between the log2 expression intensities of a probe set
and the logRratios of an snp probe.
Further details
See the Supplementary Materials and Methods.
RESULTS
ANO1 amplification and overexpression are associated
with distant metastasis
To study DNA copy-number changes in HNSCC tumours, we used
high-resolution genomic microarrays (Illumina 370K SNP) to
analyse 80 different samples. We detected a distinct peak of
frequent genomic gain at 11q13 (Figure 1). As copy-number gains
can lead to increases in gene expression, we compared these gains
with RNA levels that were determined for the same patients
(Affymetrix U133 plus 2.0 arrays; (Rickman et al, 2008)). There is a
correlation between expression levels and DNA copy numbers for
some of the genes in the 11q13 amplicon (see Table 1), as expected,
if copy-number gains increase expression. The correlation was
particularly high for some of the genes in the amplicon (PPFIA1,
OROAV1, CCND1, FADD, TPCN2, ANO1 and CTTN), suggesting
that high-level expression of these genes could be functionally
important.
Amplification and expression could be important for clinical
outcome. Our patient group allowed us to study the association of
amplification and expression with the development of future distant
metastasis (M/NM status). Using Cox univariate analysis of the
array data, we found that both amplification and expression of some
of the genes in 11q13 are correlated with M/MN status. There is a
particularly strong correlation between amplification and M/MN
status for probes located within or close to SHANK2, FGF4 and
ANO1 (see Table 1). For ANO1, the snp probe with the lowest log-
rank P-value had a relative risk of 4.3 (see Supplementary Table 1a).
There was also a strong correlation between RNA expression and M/
NM status for several genes, including FGF19, FGF4, CCND1, FADD,
ORAOV1 and ANO1 (see Table 1 and Supplementary Table 2). We
reasoned that the genes with the highest correlations could be
particularly important functionally. Using a series of cutoffs for
selection, we found that ANO1 and ORAOV1 had the best correla-
tions (Table 1). ANO1 was selected for further study because it is a
membrane protein that is exposed at the surface of the cell, which
might potentially be used for the development of antibody-based
tumour therapies. Since this choice was made, the Tumorscape
portal (http://www.broadinstitute.org/tumorscape, (Beroukhim
et al,2 0 1 0 ;B i g n e l let al,2 0 1 0 ) )p r o p o s e dt h a tA N O 1a n dF A D D
are the best candidate genes in oesophageal squamous cell
carcinoma for the 11q13 amplicon.
ANO1 overexpression in stably transfected HEp-2 cells
does not affect cell proliferation and growth in soft agar
To investigate the effects of ANO1 overexpression on tumourigen-
esis, we used the human HEp-2 cell line, which was established
from a laryngeal epidermoid carcinoma and expresses low levels of
ANO1 compared with the other HNSCC cells lines that we tested
(data not shown). We established stable HEp-2 clones that express
ANO1 and control clones with the corresponding empty vector.
Western blot analysis of the clones revealed a band at the expected
size of 100KD that was more intense in the four clones transfected
with the ANO1 expression vector (TMEM16A, abbreviated to TM
A–D; Figure 2A, lanes 4–7) compared with the three control
clones (Con A–C, lanes 1–3). To examine the effects of ANO1
overexpression on cell proliferation, we performed MTT assays.
ANO1 overexpression did not significantly affect cell growth in
normal (Figure 2B) or in low serum conditions (data not shown).
We then studied the effects of ANO1 overexpression on growth in
soft agar. There was no statistically significant difference in colony
formation between the groups of three control clones and four
ANO1-overexpressing clones (Figure 2C).
ANO1 overexpression stimulates migration and invasion
of HEp-2 cells
We used in vitro wound assays to study cell migration. Wound
closure by the ANO1-overexpressing clones was faster than the
controls throughout the time course of the experiment (Figure 3A).
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Figure 1 Genomic and transcriptomic microarray analysis of head and
neck squamous cell carcinoma (HNSCC) patient samples. Frequency of
gains and losses of chromosome 11 sequences plotted along the
chromosome. Single-nucleotide polymorphism (SNP) array data (GNL:
gain/normal/loss) were used to identify gains (red) and losses (green) along
chromosome 11. The boxed area indicates the predominant peak of
amplification corresponding to the 11q13 amplicon. The colour reproduc-
tion of the figure is available on the html full text version of the paper.
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covered by separate cells at different time points (Figure 3B). ANO1-
overexpressing cells migrated with an average speed of
0.16mmmin
–1 compared with 0.12mmmin
–1 for the controls; an
increase of B25%. The difference between the two groups of clones
was significant (Student’s t-test, Pp2 10
 05). To eliminate the
contribution of cell division to wound closure, we used 5mM
aphidicolin, which decreased DNA synthesis by 495% (data not
shown). Wound closure by the TM clones remained faster in the
presence of aphidicolin (Figure 3C). Furthermore, individual ANO1-
overexpressing cells in the presence of aphidicolin migrated with an
average speed of 0.16mmmin
–1compared with 0.1mmmin
–1for the
controls; an approximate increase of 40% (Figure 3D). These results
show that ANO1 overexpression increases cell migration, which
could account for the faster wound closure.
To study the effects of different substrates on migration, we
used Boyden chambers coated with collagen I or BSA. ANO1-
overexpressing clones migrated about two times faster than the
control clones across porous membranes coated with collagen I
(Figure 3E). Interestingly, there was no significant difference when
the membranes were coated with BSA (Figure 3E), suggesting that
interactions with collagen I are important for the effects of ANO1
on migration. We also investigated whether ANO1 overexpression
could affect migration through Matrigel plugs in Boyden chambers.
We found that invasion by the TM clones was about 50% greater
than the control clones (Figure 3F), showing that ANO1 over-
expression stimulates cell migration through Matrigel.
ANO1 overexpression affects cell adhesion, spreading and
detachment
We investigated cellular properties that could affect cell migration,
including attachment, spreading and detachment. To measure
attachment, cells were plated at the same density and incubated for
10min. In conditions in which 30–80% of the cells of ANO1-
overexpressing clones attached to the plate surface, o25% of the
control clone cells attached (Figure 4A, representative photo-
micrographs are shown for clones with median properties within their
group). These results show that ANO1 overexpression increases cell
attachment. We then investigated cell spreading. Cells that overexpress
ANO1 began to spread and form lamellipodia significantly faster than
the controls (Figure 4B, representati v ec e l l sa r es h o w n ) .T h ei n c r e a s e
was on an average about 50% greater for the ANO1-overexpressing
cells, at 2h after plating. To analyse detachment, we treated the cells
with trypsin. An average of 88% of the cells detached in the case of
the ANO1-overexpressing clones, compared with 36% for the controls
(an increase of about 40%, Figure 4C). Taken together, these results
demonstrate that ANO1 affects cell adhesion, spreading and detach-
ment in a manner that is favourable for migration.
ANO1 inhibition decreases cell migration in an
ANO1-overexpressing clone
We studied whether the effects of stable ANO1 overexpression in
the isolated clones could be transiently overcome with ANO1
Table 1 Correlation between DNA levels, RNA levels and metastasis of genes in the 11q13 amplicon
DNA : metastasis
correlation (Cox 
logrank test)
RNA :
metastasis
correlation
(Cox logrank
test)
Gene DNA gain 
frequency 
DNA :
RNA 
correlation
(Pearson
coefficient) |P<0.05| /
N
min p
C
a
n
d
i
d
a
t
e
s
 
Localisation 
MRGPRF
TPCN2 0.73 0.03
MYEOV 64%  0.2 0.04
IFITM9P  66%  –– 0.03
CCND1  68%  0.74 4/23 0.01 0.03 Soluble. non-secreted
ORAOV1  68%  0.77 0.01 0.025  +++  Soluble. non-secreted 
FGF19  68%  0.52 0.04 0.004   
FGF4  68%  0.36 0.006  0.003   
FGF3  69%  0.48 0.01 0.02   
ANO1  70%  0.68 0.007  0.035  +++  Cell surface 
FADD  70%  0.74 1/4 0.03 0.04 Soluble, non-secreted 
PPFIA1  70%  0.84 3/16 0.01 0.02 Soluble, non-secreted 
CTTN 69%  0.68 0.02 0.14     
SHANK2  64%  0.30 0.003  0.03     
C11orf76 0.01
min p
53% 0.16 0.15  0/7  0.29
51%
53% 0.27
12/36
3/8 
3/24
1/19
0/24 0.1 
0.95
0.48
+
+
+
4/4
6/10
10/19
21/39
3/5
11/18
The criteria used to select candidate genes in the 11q13 amplicon are shown sequentially in columns. The column ‘gene’ indicates the HUGO (Human Genome Organisation) gene
symbol. The column DNA gain frequency indicates the highest gain frequency (based on single-nucleotide polymorphism (SNP) gain/normal/loss status) for the SNP probes related to
the gene (filter: frequency 4 60%). The column DNA–RNA correlation indicates the highest Pearson coefficient of correlation between SNP probes and expression probe sets
related to the gene (filter: coefficient 40.6). The column DNA–metastasis correlation has two subcolumns for the N SNP probes related to the gene; the first subcolumn indicates the
number of probes with a log-rank test P-value o0.05 vs N (filter: ratio 450%), and the second subcolumn indicates the min log-rank test P-value among the N probes (filter: o0.05).
The column RNA–metastasis correlation indicates the minimum log-rank test P-value among the expression probe sets related to the gene (filter: o0.05). The column ‘candidates’
indicates the genes passing all the previous filtering steps (+++) and those passing all the previous steps except the third (DNA–metastasis correlation, |Po0.05|/N450%). The last
column, localisation, indicates an additional filtering criterion, protein localisation according to the literature, to decide between the remaining candidates.
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ssiRNAs (si2, si3 and si5, Figure 5A). The cells were transfected with
control siRNAs (siC), si2, si3 and si5, allowed to reach confluence
(24–48h later), wounded with multiple scrapes in a crisscross
manner, and after 1 and 24h harvested and used to analyse ANO1
expression by reverse transcriptase quantitative PCR and western
blotting. The ANO1 siRNAs specifically decreased ANO1 RNA
(Figures 5B) and protein (Figure 5C) expression, and the decrease
was similar at the beginning and end of the wound-healing
experiment (1 and 24h after wounding). Downregulation of ANO1
decreased wound closure to the level observed with the control
clone (Figure 5D). Wound closure was not significantly altered in the
control clone, as would be expected from the low level of endogenous
ANO1 expression in these cells (Figure 2A and data not shown).
These results indicate that the siRNAs do not have off-target effects,
and that exogenous ANO1 is involved in wound closure.
Silencing endogenous ANO1 decreases the migration
of SCC-25 cells
To study the effects of silencing endogenous ANO1 on cell migra-
tion, we used SCC-25 squamous cell carcinoma cells that express a
higher level of ANO1 than HEp-2. ANO1 knockdown during the
wound-healing assay was analysed by western blot analysis
(Figure 6A). siRNAs 2, 5 and 7 (see Figure 5A for positions)
specifically decreased the levels of ANO1. The migration of the
specific band (apparent molecular weight of 150KDa) is slower
than the form expressed in HEp-2 (Figure 2A), suggesting
dissimilar folding of this hydrophobic membrane protein during
SDS polyacrylamide gel electrophoresis. Knockdown of endo-
genous ANO1 in SCC-25 decreased wound closure throughout the
Relative number of colonies
TBP 
100 kDa Ano1
37 kDa
TM Con
MTT (595 nm)
0
0.4
0.8
1.2
1.6
0
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1.2
1.6
Time (days)
13 57
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AC BD B AC
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Con
    TM
A CBD C A B
2 4 6
048 26
Figure 2 ANO1 overexpression does not affect cell proliferation and
growth in soft agar. (A) ANO1 overexpression in stably transfected HEp-2
cells. Extracts of isolated clones (lysis buffer I) were analysed by western
blotting using the anti-ANO1 antibody. TM-A, TM-B, TM-C and TM-D:
ANO1-overexpressing clones; A, B and C: control clones established using
the corresponding empty vector. (B) Cell proliferation measured by the
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay
for the three control (dotted line) and four TM (solid line) clones. MTT
conversion was measured at 595nm. This experiment was repeated three
times and similar results were obtained (four independent experiments).
(C) Colony formation in soft agar. The number of colonies in each
experiment were normalised to TM-A. The Student’s t-test for the control
clones (hatched) and the ANO1-overexpressing clones (black) gave a
P-value of 0.06, which we consider to be not significant. This experiment
was repeated once (i.e., two independent experiments) and similar results
were obtained.
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Figure 3 ANO1 overexpression stimulates cell migration and invasion.
(A, C) In vitro wound healing assays in the absence (A) or presence of 5mM
aphidicolin (C). The mean values were calculated for the control clones
(dotted line) and for the overexpressing clones (solid line). (B, D) Rate of
individual cell migration. The distance covered by individual cells was
measured at different times of wound healing using Image J. The P-value
between the controls (Con) and the overexpressing clones (TM) was
p2 10
 05.( E) Boyden chamber migration assay. The cells that migrated
through the porous membranes coated with BSA or collagen I (Col I) were
quantified 2.5h after seeding. The results are the averages from two
independent experiments (Student’s t-tests: BSA, P¼0.35; Col I,
P¼2 10
 4). (F) Boyden chamber invasion assay. Invading cells were
quantified 5.5h after seeding. The results are the averages from two
independent experiments (Student’s t-test, P¼0.002). The dotted lines in
(E) and (F) indicate the average values for each group of stable clones.
*Indicates statistical significance (P-value o0.05).
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stime course of the experiment (Figure 6B). These results reinforce
the overexpression data, and show that ANO1 is involved in wound
closure and movement.
CaCC blockers decrease cell migration in
ANO1-overexpressing clones
To investigate whether ANO1 channel activity is required for
cell migration, we used the inhibitor niflumic acid (NA) (Caputo
et al, 2008; Schroeder et al, 2008; Yang et al, 2008). Concentrations
of 10 and 100mM NA delayed wound filling by the ANO1-
overexpressing cells compared with untreated cells, whereas they
had little effect on the control clones (Figure 7A; the photographs
show TM-A and the control clone A; Figure 7B; shows the average
values for the groups of TM and control clones). The lack of an
effect on the control clones is expected, as they expressed low
levels of ANO1. Furthermore, it indicates that the effect of NA is
specific for ANO1. To investigate the pharmacological profile
of inhibition, we tested DIDS, which inhibits the CaCC activity
of ANO1 ((Schroeder et al, 2008; Yang et al, 2008), and as negative
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scontrols DCPIB (a fairly specific inhibitor of volume-sensitive
chloride channels) and CFTRinh172 (a selective inhibitor of
CFTR). We first determined their IC10 values using MTT assays
under the conditions used for wound closure (freshly confluent
cells, 48h; Figures 8A–D). The IC10 values for each compound
were similar for the control and ANO1-overexpressing clones (NA
100±20mM, DIDS 300±50mM, DCPIB 10±3mM; CFTRinh172
5±2mM), showing that there was little variation in sensitivity
between the clones. Using concentrations of the compounds close
to the IC10 (NA, DCPIB and CFTRinh172) or lower (DIDS,
100mM), we found that DIDS specifically inhibited wound closure
of the ANO1-overexpressing clones, similar to NA, whereas DCPIB
and CFTRinh172 had no significant effects (Figure 8E). In
addition, the ANO1 CaCC inhibitor fluoxetine (10mM; IC10
20mM, data not shown) (Yang et al, 2008) also specifically
inhibited the TM clones. These results suggest that CaCC activity
is required for the effects of ANO1 on cell motility.
DISCUSSION
In this study, we show that amplification of the 11q13 locus, and
ANO1 copy number and expression are significantly augmented
in patients with an increased propensity to develop metastases.
ANO1 is involved in biological functions that are important for
metastasis, including migration, invasion and adhesion, but
apparently not for proliferation and growth in soft agar. CaCC
activity in cells that overexpress ANO1 is important for cell
motility.
From the analysis of 80 patient samples with SNP arrays, we
found that amplification of the 11q13 locus is associated with the
propensity for the development of metastasis in HNSCC. We also
found this association (Cox log-rank P¼0.05, Supplementary
Table 1b) using the same patient samples in our previous BAC
array-based study (Rickman et al, 2008), but the lower resolution
(4.7K compared with 370K probes) prevented precise identifica-
tion of candidate genes. Other studies have indicated that 11q13
amplification is associated with poor prognosis in HNSCC
(Akervall et al, 1995, 1997; Klussmann et al, 2009) and is also
associated with patient outcome in other cancers (Berenson et al,
1990; Kitagawa et al, 1991; Borg et al, 1991). Further studies with
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sprospective samples will be required to evaluate whether
amplification of 11q13 is a useful marker for metastatic outcome.
The high resolution of the arrays allowed us to identify SNPs
within the amplicon that are associated with metastatic outcome.
The highest correlations, using either log-rank test P-values
(Po0.05) or relative risk, were for probes close to SHANK2,
FGF4 and ANO1, and close to SHANK2, ANO1 and CTTN,
respectively (Supplementary Table 1a). However, other probes
throughout the amplicon were also associated with metastatic
outcome, suggesting that there is no particular subregion that
could be implicated in this process. These results are compatible
with several other studies that used lower resolution approaches
and that suggested that the whole amplicon should be considered
as the functional element (Gibcus et al, 2007; Huang et al, 2006).
We localised the amplicon to 68.5–70.3Mb (HG18), in agreement
with others (Huang et al, 2006; Gibcus et al, 2007; Reshmi et al,
2007). We also observed a high frequency of loss of 11q distal
to the 11q13 amplicon, which has been proposed to drive
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stumourigenesis and amplification through effects on DNA repair
and expression of miR-125b and miR-100 (Parikh et al, 2007;
Henson et al, 2009). Increased DNA copy number in the 11q13
amplicon is associated with overexpression of several genes. We
found a particularly high correlation between copy number and
expression for six genes: PPFIA1, ORAOV1, CCND1, FADD, TPCN2
and ANO1 (in their order of correlation). A similar correlation has
been reported for cell lines from oral squamous cell carcinoma
(TPCN2, CCND1, ORAOV1, ANO1, FADD, PPFIA1 and EMS1
(Huang et al, 2006); FADD, PPFIA1 and EMS1 (Jarvinen et al,
2008)). The expression of the six genes identified in our study was
also highly correlated with metastatic outcome: PPFIA1, ORAOV1,
TPCN2, CCND1, ANO1 and FADD, in the order of log-rank test
P-values. Interestingly, 11q13 amplification has been related with
nodal metastases and higher tumour recurrence rates in hypo-
pharyngeal HNSCC (Rodrigo et al, 2002). EMS1 expression has
been shown to predict poor survival in laryngeal carcinoma
(Gibcus et al, 2008; Rodrigo et al, 2009). Some of these genes have
functions that are significant for tumourigenesis, suggesting that
they may drive the amplification (Martin et al, 2008). CCND1, the
most studied gene, is involved in cell-cycle progression (Jares et al,
1994; Michalides et al, 1995, 1997). PPFIA1 may regulate
disassembly of focal adhesions and cell–matrix interactions
(Serra-Pages et al, 1998). ORAOV1 is required for cell growth
and tumour angiogenesis (Jiang et al, 2008). FADD, in its
phosphorylated nuclear form, is associated with increased cell
proliferation (Werner et al, 2006). The possibility exists that
several genes in the 11q13 could contribute to patient outcome
(Huang et al, 2006), and that the other less characterised genes
may also contribute. We selected ANO1 for further study, because
of the correlation with 11q13 amplification and metastatic
outcome, and its localisation on the cell surface. Furthermore,
ANO1 is not amplified and overexpressed in tumours that express
HPV E6 and E7. Interestingly, these patients have a better
prognosis (Ragin et al, 2006; Klussmann et al, 2009; Jung et al,
2010).
We have shown that ANO1 overexpression does not significantly
affect cell proliferation during the exponential growth phase, nor
anchorage-independent growth in soft agar, a common assay for
tumourigenicity. Interestingly, ANO1 overexpression does stimu-
late migration, which is important for metastasis. We have shown
that ANO1 overexpression accelerates in vitro wound healing on
cell culture plates and movement through membranes in Boyden
Chambers. Faster wound closure could have resulted from effects
on cell division, spreading and movement. Increased cell
proliferation did not contribute significantly, as aphidicolin (an
inhibitor of DNA replication) did not have a significant effect.
Furthermore, there was no effect of ANO1 overexpression on
growth. Direct measurements of individual cells showed that they
moved more quickly. In the Boyden chamber assays, the cells
overexpressing ANO1 crossed through the pores of the membranes
more quickly when they were coated with collagen I, but not when
they were coated with BSA. This result suggests that the effects of
ANO1 depend on attachment to the extracellular matrix. This
could somehow involve integrins, the largest family of receptors
that mediate cell adhesion to collagens, fibronectin and laminins
(Heino and Kapyla, 2009). We have shown that ANO1 over-
expression stimulates cell attachment, spreading and detachment,
which are important for cell movement (Ruoslahti and Obrink,
1996; Webb et al, 2002). Increased movement could also account
for the increased ability of overexpressing cells to migrate through
Matrigel, although we cannot exclude that other mechanisms could
also be involved.
We also investigated a cell line (SSC-25) that expresses a
relatively high level of ANO1, which reflects the situation in the
majority of HPV-negative HNSCC. Downregulation of endogenous
ANO1 in SSC-25 inhibited cell movement, showing that the
endogenous protein is involved in this process. This result is
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ssignificant as ANO1 could be subjected to modifications that are
not reproduced in the overexpressing cell clones. Furthermore,
ANO1 is a complex and poorly characterised gene with different
splice variants (Ferrera et al, 2009). We observed, using SDS
polyacrylamide gel electrophoresis, that ANO1 from SSC-25
migrated differently from the exogenously introduced protein.
This may not be significant, as we found that the migration of
ANO1 is quite variable depending on the conditions of extraction
and denaturation. Furthermore, hydrophobic proteins have been
shown to fold variably in SDS (Rath et al, 2009). However, we
cannot exclude that the endogenous protein is somehow different.
We found that three different siRNAs that target known transcripts
had similar effects and gave results that were consistent with the
overexpression data. This suggests that there are no major
functional differences relating to cell movement between the
exogenous and endogenous proteins. Some of the reported ANO1
cDNAs could code for proteins with different numbers of
transmembrane domains. However, there are no reports that
proteins with less than eight transmembrane segments are
functional and are physiologically relevant. Recently, three splice
variants have been described that affect the chloride channel
properties of ANO1 (Ferrera et al, 2009). The significance of these
new finding are interesting areas for future studies.
Our results show that amplification and overexpression of
ANO1 and other genes on the 11q13 are associated with an
increased frequency of future distant metastasis of HPV-negative
HNSCC. ANO1 may contribute to this susceptibility in a quite
specific manner, through effects on cell migration rather than
growth. Additional metastatic properties could be provided by
collaborating genes that are co-amplified and overexpressed, such
as CCND1 for growth (Perez-Ordonez et al, 2006). Functional
collaboration between different genes may contribute to their high
frequency of co-amplification in the 11q13 locus. However, it
should be strongly stressed that the data do not allow us to
conclude that ANO1 (or any of the other genes) is responsible for
the metastatic behaviour of patients with 11q13 amplification.
We have shown that several compounds that have been shown
to inhibit the CaCC activity of ANO1 (NA, DIDS and fluoxetine
(Schroeder et al, 2008; Yang et al, 2008)) specifically reduce
migration of the ANO1-overexpressing cells, but not the parental
clones that do not express significant levels of ANO1. Several
control compounds, DCPIB (an inhibitor of volume-sensitive
chloride channels) and CFTRinh-172 (a selective inhibitor of
CFTR), do not have a significant effect. This suggests that the
effects are due to the blockage of CaCC activity, rather than some
other activity that this protein may have. However, it should be
stressed that NA and the other inhibitors are not ANO1 specific
(Schultz et al, 1999; Verkman and Galietta, 2009). Similar to our
results, Mao et al (2005) have shown that blocking Cl
  ion
channels inhibits migration of nasopharyngeal carcinoma cells.
However, our study does not show that there is a direct correlation
between the CaCC activity of ANO1 and migration, and further
studies of chloride levels changes, using patch-clamp or other
techniques (Bregestovski et al, 2009; Verkman and Galietta, 2009)
will be required. The mechanisms of these processes and the
contribution of chloride and calcium are interesting subjects for
further study (Kunzelmann et al, 2009).
Considerable evidence exists for the contribution of ion
channels to tumour development, growth and malignancy
(Kunzelmann, 2005). Chloride channels are relatively unexplored
as drug targets for many pathologies, and both inhibitors and
activators are being developed (Verkman and Galietta, 2009). Our
observations indicate that activators of ANO1, which may be useful
in other pathological settings (e.g., compensation for the inactive
CFTR chloride channel in cystic fibrosis), could potentially have
undesirable effects on tumours through ANO1. Our study high-
lights that understanding the roles of ANO1 in cancer metastasis
will be important in the rational design of drugs for this important
class of targets.
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